Digital Respiratory Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Smart Inhalers & Nebulizers, Sensors & Apps, Others), By Indication (Asthma, COPD, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 44.98 Billion
CAGR (2026-2031)	10.32%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America
Market Size (2031)	USD 81.09 Billion

Market Overview

The Global Digital Respiratory Devices Market will grow from USD 44.98 Billion in 2025 to USD 81.09 Billion by 2031 at a 10.32% CAGR. The Global Digital Respiratory Devices Market encompasses smart inhalers, nebulizers, and spirometers integrated with sensors and connectivity features to track medication adherence and lung physiology. The primary drivers supporting market growth include the escalating prevalence of chronic respiratory conditions and the increasing demand for remote patient monitoring solutions that facilitate timely medical interventions. According to the European Respiratory Society, in 2025, chronic respiratory diseases affected 81.7 million people in the WHO European Region, emphasizing the critical need for advanced management tools.

However, the substantial cost associated with developing and procuring these advanced connected technologies poses a significant challenge that could impede market expansion. Limited reimbursement frameworks in many nations often make these devices unaffordable for a large segment of the population, thereby restricting their adoption in regions with limited healthcare funding. This financial barrier remains a primary obstacle to the widespread implementation of digital respiratory solutions globally.

Key Market Drivers

The escalating global prevalence of asthma and COPD serves as a fundamental catalyst for the Digital Respiratory Devices Market, necessitating advanced tools for disease management. Providers increasingly rely on smart inhalers to prevent exacerbations, a demand amplified by deteriorating environmental conditions. According to the American Lung Association, April 2024, in the 'State of the Air 2024' report, approximately 131 million people in the United States live in areas with unhealthy levels of air pollution, creating significant risk for respiratory complications. Consequently, the patient volume requiring long-term care drives the integration of digital solutions to monitor lung physiology. Validating this burden, the Asthma and Allergy Foundation of America, September 2024, in the '2024 Asthma Capitals Report', highlighted that nearly 28 million Americans live with asthma, underscoring the need for scalable strategies.

Simultaneously, the surge in adoption of remote patient monitoring (RPM) and telehealth solutions is transforming care delivery by shifting treatment to patient homes. This transition is powered by IoT connectivity, allowing real-time data transmission and personalized adjustments without frequent hospital visits. By enabling proactive interventions, these technologies improve adherence and clinical outcomes. The scale of this penetration is evident in industry data; according to ResMed, September 2024, in the '2024 Investor Day Presentation', the company has deployed over 26 million connected devices globally. This widespread connectivity establishes the infrastructure necessary for value-based care, ensuring digital respiratory devices become a standard component of modern medicine.

Download Free Sample Report

Key Market Challenges

The substantial capital required to develop and procure connected respiratory technologies presents a formidable barrier to market expansion. Manufacturers incur significant expenses during the research and engineering phases of these complex systems, which inevitably translates into higher retail prices for smart inhalers and monitoring devices. Furthermore, the absence of comprehensive reimbursement policies in many regions forces patients to bear these costs out-of-pocket. This lack of funding makes it difficult for healthcare systems, particularly in economically constrained regions, to justify the investment in digital tools over traditional, less expensive alternatives.

This economic friction directly impedes the uptake of digital solutions, keeping market penetration levels below their potential. The high baseline cost of managing respiratory conditions already strains patient finances, making the additional expense of unsubsidized digital devices prohibitive. According to the Asthma and Allergy Foundation of America, in 2025, patients with asthma faced annual medical expenses that were $3,266 higher than those for individuals without the condition. This disparity underscores the severe economic constraints that prevent the widespread integration of digital tools into standard care protocols, thereby stalling the overall growth of the global market.

Key Market Trends

Strategic collaborations between pharmaceutical entities and medical technology firms are fundamentally reshaping the market, moving beyond simple vendor relationships to co-development models that bundle medication with digital connectivity. These partnerships allow pharmaceutical companies to leverage established sensor technologies for improved adherence tracking while offering device manufacturers access to vast patient networks and distribution channels. This synergistic approach is validating the commercial viability of connected ecosystems, as evidenced by the operational scaling of key players in the sector. According to Adherium, December 2025, in the 'Adherium Surpasses CY2025 Shipment Milestones' announcement, the company validated this growth trajectory by delivering 4,666 connected devices, surpassing its calendar year targets and confirming the rising demand for integrated respiratory monitoring solutions.

Simultaneously, the emergence of eco-friendly and sustainable device designs is gaining critical momentum as manufacturers respond to intensifying regulatory pressure to decarbonize respiratory care. This trend drives the engineering of inhalers that utilize low-global-warming-potential propellants and reusable components, significantly lowering the environmental footprint of asthma and COPD management without compromising clinical efficacy. Corporations are aggressively investing in green innovation to align with global environmental, social, and governance (ESG) mandates. According to Chiesi Farmaceutici, June 2025, in the 'Sustainability Report 2024', the company is advancing its development of a Carbon Minimal Inhaler, which is engineered to reduce propellant gas emissions by up to 90% compared to traditional hydrofluorocarbon-based devices.

Segmental Insights

The Online Pharmacies segment is identified as the fastest-growing distribution channel within the Global Digital Respiratory Devices Market, driven by the increasing adoption of telehealth and digital procurement methods. This expansion is supported by the convenience of doorstep delivery for smart inhalers and nebulizers, which is essential for patients managing chronic respiratory conditions. Furthermore, approvals from regulatory bodies such as the U.S. FDA for connected health technologies have bolstered consumer confidence in purchasing medical devices through verified internet portals. Consequently, patients increasingly prefer these platforms for their accessibility, competitive pricing, and seamless integration with digital prescription services.

Regional Insights

North America maintains a leading position in the Global Digital Respiratory Devices Market due to the high prevalence of chronic respiratory conditions and the widespread adoption of connected healthcare solutions. The region benefits from a strong presence of major device manufacturers and established healthcare infrastructure that supports the distribution of smart inhalers and sensors. Furthermore, favorable reimbursement policies from the Centers for Medicare & Medicaid Services encourage the utilization of these technologies in patient management. This market expansion is also facilitated by the US Food and Drug Administration, which provides clear regulatory pathways for digital health product approvals.

Recent Developments

• In November 2025, Teva Pharmaceuticals launched Teva Rise, a global open innovation platform intended to accelerate the integration of artificial intelligence and digital health technologies into its operations. The initiative invited startups to collaborate on solving critical challenges across research, manufacturing, and patient care. The company aimed to leverage these partnerships to develop smart manufacturing processes and advanced digital health tools, potentially benefiting its extensive respiratory portfolio. This strategic move was designed to foster the co-creation of scalable solutions that could improve treatment adherence and clinical outcomes for patients utilizing their pharmaceutical products.
• In September 2024, ResMed introduced new patient-centric digital solutions by integrating its myAir consumer app with Apple and Android smartwatches. This update allowed users to view their nightly sleep data and therapy insights directly on their wearable devices. The company stated that the integration was designed to make it easier for patients to track their sleep apnea treatment and stay engaged with their therapy. The launch addressed the growing demand for wearable health technology and aimed to empower individuals to take a more active role in their sleep health management through accessible digital tools.
• In September 2024, Aptar Digital Health announced a collaboration with Guy's and St Thomas' NHS Foundation Trust to evaluate the impact of its Respiratory Disease Management Platform on asthma patients. The initiative involved a clinical study to assess improvements in symptom control among adults with moderate to severe asthma. The digital platform was designed to empower patients by offering real-time medication tracking, reminders, and educational resources via a mobile app. The company aimed to demonstrate how digital solutions could reduce rescue medication usage and unnecessary healthcare visits by fostering better disease management and adherence.
• In May 2024, Adherium announced that AstraZeneca had selected its Hailie Smartinhaler platform for a clinical trial aimed at recording and transferring medication usage data. The contract, valued at $1.1 million, involved the deployment of the company's digital devices over a three-year period to accurately track inhaler adherence. The company highlighted that this partnership underscored its commitment to improving patient outcomes through advanced monitoring technology. The Hailie platform utilizes a secure cloud-based system to provide healthcare professionals with actionable insights for managing patients with severe asthma and chronic obstructive pulmonary disease.

Key Market Players

• COHERO Health Inc.
• Cognita Labs llc
• Adherium Limited
• Amiko Digital Health Limited
• Teva Pharmaceuticals Industries Ltd.
• Propeller Health
• Novartis AG
• Pneuma Respiratory Inc.
• 3M Health Care Limited
• AireHealth, Inc.

By Product	By Indication	By Distribution Channel	By Region
Smart Inhalers & Nebulizers Sensors & Apps Others	Asthma COPD Others	Hospital Pharmacies Retail Pharmacies Online Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Digital Respiratory Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Digital Respiratory Devices Market, By Product:

• Smart Inhalers & Nebulizers
• Sensors & Apps
• Others

• Digital Respiratory Devices Market, By Indication:

• Asthma
• COPD
• Others

• Digital Respiratory Devices Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

• Digital Respiratory Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE